63 Result(s)
within
Kong** Wu
Cancer Research
-
Article
Open AccessOrganoid technology in disease modelling, drug development, personalized treatment and regeneration medicine
Organoid technology bridges the gap between conventional two-dimensional cell line culture and in vivo models. The near-physiological technology can virtually recapitulates organ development and human diseases...
-
Article
Open AccessRecent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy
Angiogenesis has always been the topic of major scientific interest in the field of malignant tumors. Nowadays, targeting angiogenesis has achieved success in various carcinomas by several mechanisms, includin...
-
Article
Open AccessSynergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment
Immune checkpoint inhibitor (ICI) activates host’s anti-tumor immune response by blocking negative regulatory immune signals. A series of clinical trials showed that ICI could effectively induce tumor regressi...
-
Article
Open AccessActivating cGAS-STING pathway for the optimal effect of cancer immunotherapy
During tumor progression, a subset of cancer cells escape from immune surveillance and eventually develop into measurable tumor mass. Cancer immunotherapy eradicates tumor cells by enhancing multiple steps in ...
-
Article
Open AccessA novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells
Human epidermal growth factor receptor 2 (HER2) is overexpressed in multiple cancers, which is associated with poor prognosis. Herceptin and other agents targeting HER2 have potent antitumor efficacy in patien...
-
Article
Open AccessNext generation chimeric antigen receptor T cells: safety strategies to overcome toxicity
Chimeric antigen receptor T (CAR-T) cell therapy is an emerging and effective cancer immunotherapy. Especially in hematological malignancies, CAR-T cells have achieved exciting results. Two Anti-CD19 CAR-T the...
-
Article
Open AccessProspects for combining immune checkpoint blockade with PARP inhibition
The immunogenicity of a cancer cell is derived from accumulated somatic mutations. However, on the contrary to increased immunogenicity, anti-cancer immune response tends to be feeble. This impaired anti-cance...
-
Article
Open AccessThe efficacy and safety of combination of PD-1 and CTLA-4 inhibitors: a meta-analysis
Recently, a series of clinical trials showed that combination of anti-programmed cell death-1 (α-PD-1) and anti-cytotoxic T-lymphocyte-associated protein 4 (α-CTLA-4) could effectively eliminate tumor. However...
-
Article
Open AccessNovel immune checkpoint targets: moving beyond PD-1 and CTLA-4
The emergence of immune checkpoint inhibitors (ICIs), mainly including anti-programmed cell death protein 1/programmed cell death ligand 1 (PD-1/PD-L1) and anti-cytotoxic T lymphocyte-associated antigen-4 (CTL...
-
Article
Open AccessAdvances and perspectives of PARP inhibitors
DNA damage repair deficiency leads to the increased risk of genome instability and oncogenic transformation. In the meanwhile, this deficiency could be exploited for cancer treatment by inducing excessive geno...
-
Article
Open AccessImmune pressures drive the promoter hypermethylation of neoantigen genes
Cancer cells with strong immunogenicity are susceptible for elimination by cancer immunoediting, while the subpopulations with weak immunogenicity survive. As a result, a subset of cancer cells evade the immun...
-
Article
Open AccessThe role of cancer-derived microRNAs in cancer immune escape
During malignant transformation, accumulated somatic mutations endow cancer cells with increased invasiveness and immunogenicity. Under selective pressure, these highly immunogenic cancer cells develop multipl...
-
Article
Open AccessThe global burden and attributable risk factor analysis of acute myeloid leukemia in 195 countries and territories from 1990 to 2017: estimates based on the global burden of disease study 2017
Acute myeloid leukemia (AML) is a common leukemia subtype and has a poor prognosis. The risk of AML is highly related to age. In the context of population aging, a comprehensive report presenting epidemiologic...
-
Article
Open AccessRDGN-based predictive model for the prognosis of breast cancer
Breast cancer is the most diagnosed malignancy in females in the United States. The members of retinal determination gene network (RDGN) including DACH, EYA, as well as SIX families participate in the prolifer...
-
Article
Open AccessThe global, regional, and national burden of kidney cancer and attributable risk factor analysis from 1990 to 2017
Kidney cancer’s incidence and mortality vary in different regions and countries. To compare and interpret kidney cancer’s burden and change trends in the globe and in different countries, we conducted this stu...
-
Article
Open AccessCD44 as a tumor biomarker and therapeutic target
CD44, a complex transmembrane glycoprotein, exists in multiple molecular forms, including the standard isoform CD44s and CD44 variant isoforms. CD44 participates in multiple physiological processes, and aberra...
-
Article
Open AccessRegulation of PD-L1 expression in the tumor microenvironment
Programmed death-ligand 1 (PD-L1) on cancer cells engages with programmed cell death-1 (PD-1) on immune cells, contributing to cancer immune escape. For multiple cancer types, the PD-1/PD-L1 axis is the major ...
-
Article
Open AccessMiRNA-mediated EMT and CSCs in cancer chemoresistance
Cancer stem cells (CSCs) are a small group of cancer cells, which contribute to tumorigenesis and cancer progression. Cancer cells undergoing epithelial-to-mesenchymal transition (EMT) acquire the chemoresista...
-
Article
Open AccessThe construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-β and PD-L1
Therapeutic antibodies targeting programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) axis induce potent and durable anti-tumor responses in multiple types of cancers. However, only a subse...
-
Article
Open AccessPredictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
Immunotherapy, especially anti-programmed cell death protein 1/programmed cell death ligand 1 (PD-1/PD-L1) treatment has significantly improved the survival of non-small cell lung cancer (NSCLC) patients. Howe...
